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In the fight against malaria new medicines are an essential weapon. For the parts of the world where the current
gold standard artemisinin combination therapies are active, significant improvements can still be made: for example
combination medicines which allow for single dose regimens, cheaper, safer and more effective medicines, or
improved stability under field conditions. For those parts of the world where the existing combinations show less
than optimal activity, the priority is to have activity against emerging resistant strains, and other criteria take a
secondary role. For new medicines to be optimal in malaria control they must also be able to reduce transmission
and prevent relapse of dormant forms: additional constraints on a combination medicine. In the absence of a
highly effective vaccine, new medicines are also needed to protect patient populations. In this paper, an outline
definition of the ideal and minimally acceptable characteristics of the types of clinical candidate molecule which are
needed (target candidate profiles) is suggested. In addition, the optimal and minimally acceptable characteristics of
combination medicines are outlined (target product profiles). MMV presents now a suggested framework for
combining the new candidates to produce the new medicines. Sustained investment over the next decade in
discovery and development of new molecules is essential to enable the long-term delivery of the medicines
needed to combat malaria.
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Malaria is a critical public health challenge, historically be-
ing responsible for the deaths of millions, particularly
young children and expectant mothers. The past decade
has seen significant progress in the control of malaria,
with a reduction in reported cases [1]. There were 655,000
deaths reported in 2010 from over 200 million cases,
down from over a million a decade ago. This success has
been accomplished mostly by the expanded use of com-
bination medicines, insecticide-treated nets (ITNs) and
indoor residual spraying (IRS). Provided that current levels
of political and financial support for malaria control are
sustained, these numbers are expected to continue to fall
over the next decade with increased distribution of control
measures and with the potential of a vaccine being
launched in 2015 [2]. In parallel with this progress, our* Correspondence: wellst@mmv.org
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reproduction in any medium, provided the orunderstanding of the biology of the parasite has entered a
new era. With the sequencing of the parasite genomes
[3-5], new potential drug targets have emerged. Powerful
new screening and imaging technologies have also made it
possible to screen millions of compounds directly against
the parasite in culture. This has led to the identification of
many new active molecules against the erythrocytic stages
of malaria, several of which are now in clinical develop-
ment, and the identification of a new generation of
molecular targets [6-8].
Two major types of challenge for the development of
new medicines against malaria remain: those external to
the drug discovery community, and those internal. The ex-
ternal challenge is the changing malaria landscape. Emer-
gence and spread of resistance are always major concerns
in infectious disease, and recent reports in the literature
confirm decreased patient responses to artemisinin deriva-
tives in South-East Asia [9,10] combined with decreasing
efficacy of the partner drugs used in artemisinin combin-
ation therapy (ACT) [11]. Replacements for artemisinin-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gently required. Ideally at least one component needs to
be as fast-acting as the artemisinin derivatives to provide
rapid relief of symptoms (the community has come to
expect this), and as affordable as chloroquine was when it
was used as first-line treatment. Modeling studies under-
line the key role that medicines can play in malaria eradi-
cation [12,13]. Medicines can be used both to treat
patients’ symptoms and cure them of acute disease, as well
as prophylaxis or chemoprotection, and these can play a
complementary role alongside a partially effective vaccine
[12,13]. Animal studies warn that parasites which escape
from a partially effective vaccine may gain in virulence in
a process more sophisticated than simple antigenic drift
[14]. In addition, there are indications that the mosquito
vector (Anopheles) is developing behavioural strategies to
evade ITNs [15], and resistance to the pyrethroid class of
insecticides used in the nets is increasing. The cost of fail-
ure in malaria control is high: the historical experience
with chloroquine and DDT resistance shows that the loss
of frontline interventions can have a devastating effect on
the impact of the disease if a new generation of therapies
and other interventions are not available.
Other public health factors will influence the type of
medicines needed in the future, such as the need for anti-
malarial treatments for patients who are already receiving
treatment for Human Immunodeficiency Virus (HIV),
tuberculosis (TB) or other co-infections. Co-treatment for
HIV infection is especially relevant due to risks for inter-
actions between the medicines used to treat HIV and
those for malaria, through interference with metabolic
pathways involving cytochromes, especially P450 3A4.
This increases the risks for altered pharmacokinetics lead-
ing to either reduced efficacy or enhanced drug exposure
and side effects. In addition the pathology of co-infection
means that such patients are especially vulnerable, and
this may present additional constraints for the safety of
new medicines. Finally, the chemical stability of new medi-
cines is another key challenge. Fixed-dose artemisinin
combination therapies are stable in Zone IV conditions
(37°C, high relative humidity) for 2–3 years. Given the
difficulties of distribution, then any improvement over this
level of stability would be of considerable advantage in the
future.
In addition, there are internal factors, within the com-
munity, which arise from the new goal of long-term mal-
aria eradication. These bring additional challenges in drug
discovery beyond those required by medicines that effect
simple case control. First, the new medicines need to be
able to reduce and, ideally, prevent transmission from one
infected patient to the next (R0 < <1). Second, they need to
safely prevent the relapses with Plasmodium vivax
and Plasmodium ovale. Third, significant post-treatment
prophylaxis (treatment of a malaria case providingprotection against future infection) may help to reduce
the clinical burden of malaria especially in high-
transmission areas. Fourth, new medicines will be needed
for chemoprotection (causal or chemoprophylaxis) that
are necessary to protect vulnerable populations such as in-
fants and expectant mothers. All of these medicines must
be safe enough for use in sensitive patient groups, includ-
ing pregnant women [12], the youngest of children [16]
and patients with other co-morbidities, such as HIV and
TB infection, or malnutrition, and correct doses must be
selected for each groups. It is important to emphasize that
due to the combination of these constraints there is
unlikely to be a one-size-fits-all solution in the campaign
to eliminate malaria; indeed many of these issues cannot
be de-risked until Phase IV.
Typically, a potential medicine for an infectious dis-
ease should take about twelve years on the journey from
the first hypothesis to registration, provided funding is
not limiting. In the case of malaria, timelines for the dis-
covery and development of new medicines are longer
because of the need for combinations, but there are
improvements in the early stages with some molecules
moving from screening to human proof-of-concept in
five years. Nonetheless, the complexity of combination
therapies (which require additional steps in develop-
ment), and registration in highly diverse countries means
that the overall project timeline to launch in disease-
endemic countries will probably remain at 12–15 years.
With these long timelines it is essential to start out with
a clear idea of what success will look like: what are the
anticipated needs in the clinic at the time of launch,
what is the ideal clinical candidate molecule, and how
will these be combined, with existing therapies, into the
ideal final product? This requires a clear hypothesis or
hypotheses as to how the medical need will change over
the next fifteen years. The description of the desired
product is captured in what is known as the Target
Product Profile (TPP). It is important also to underline
that the target product profile can vary with different
external factors. The clearest example here would be the
spread of ‘artemisinin resistance’. Obviously, in countries
or districts where no ACT is clinically effective, the TPP
will be different from those where current therapy is still
fully active. Since for malaria, the medicine, or target
product will contain more than one active ingredient,
the attributes of a target product profile can be divided
into many different target candidate profiles (TCP), each
of which is effectively the job description for a new mol-
ecule entering clinical development. Exactly how the
overall list of attributes needed in the final product is
divided between the different molecules it contains and
indeed how many different components are needed will
be a matter of much debate, and there are many differ-
ent potential solutions. However, this debate will be
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in patients is seen, a theme which is explored later in
this paper. The other reality check in this process is pro-
vided by comparison to existing medications, which act
as the gold standards for clinical trials in terms of safety,
efficacy, potential for transmission-blocking and relapse
prevention, cost of goods, and overall convenience. It is,
therefore, important to ask continually which potential
benefits a new molecule will bring compared with
existing molecules (both those which have been
approved, and those in development), throughout the
discovery and lead optimization process.
After some years of stagnation, the global pipeline of
malaria medicines in development is now progressing as
a result of significant investments over the past decades.
This fresh acceleration raises an additional complication:
that the minimum requirements for new medicines are
not fixed, but are continually moving. As the number of
molecules with the potential to meet a particular TCP
increases, then the standards for new molecules will
move higher. Conversely, if clinical candidates are lost
from the portfolio due to safety considerations or the
emergence of resistance, the bar may be lowered, though
the shortcomings of the failed drug, whether safety or
efficacy, will still need to be overcome. It is likely that
compounds will be parked at various stages of the pre-
clinical and clinical development processes such that
they can then be reactivated in response to factors exter-
nal to each individual project, such as spread of resist-
ance to a mainstay therapy. This underlines the need for
all drug discoverers to have access to a clear and accur-
ate picture of all molecules in development. A detailed
review of the global landscape was recently published
[17]. An online global malaria medicines portfolio map,
updated every three months, can be found on the MMV
web site [18]. Recommendations for both TPPs and TCPs
need to be viewed in the context of the malERA - the Mal-
aria Eradication Agenda, which set out to characterize the
changes needed to malaria research to accommodate de-
clining malaria incidence in some countries and the pro-
spect of local malaria elimination. These include
considerations for drug discovery [19] alongside other
strategies for malaria eradication [20-28]. The strategy
outlined the advantages of medicines that could be given
as a Single Exposure Radical Cure and Prophylaxis (abbre-
viated to SERCaP). Radical in this context refers to the re-
moval of all species of Plasmodium in a patient, including
the dormant liver stages or hypnozoites and asymptomatic
sexual stages or gametocytes. This medicine should wher-
ever possible be given as directly observed therapy (DOT),
to ensure compliance, even in challenging field conditions;
as such, the SERCaP represents the ideal treatment. It is
important to underline that this may not be achievable,
and so compromises will undoubtedly have to be madealong the way. For this reason this paper provides two def-
initions, an ideal and a minimally acceptable product. A
second class of medicine, a new generation of prophylac-
tics was also suggested, which would be needed in coun-
tries which have eliminated malaria, but where a local
resurgence of infection could occur.
Historically, MMV played a role in coordinating pro-
posals for TPPs describing both the ideal and minimally
acceptable profile for new medicines. The last version con-
centrated more on the product profiles rather than the
candidate profiles, and was produced with the External
Scientific Advisory Committee of Medicines for Malaria
Venture in 2010. In the present publication, definitions for
the attributes of individual molecules (TCPs), and for the
final combination product (TPPs) are laid out. The TPPs
fall into two groups: medicines which can be used to cure
patients, and medicines which can be used to protect pop-
ulations from infections. The scientific justification and ra-
tionale behind these updated recommendations are
presented, as well as some of the currently unanswered
questions. Strategies for combining the individual candi-
date molecules to produce the products are discussed, and
this is one area where there are potentially many solutions
to the same problem. The malaria drug discovery portfolio
certainly appears stronger than a decade ago. However,
there are now enough data to characterize success rates.
This enables a characterization of the unmet needs in
terms of how many new molecules will be required in the
future.
General considerations across all TCPs for next-generation
malaria medicines
Several characteristics of each candidate molecule are
common across all of the different TCPs and can be
discussed in general terms.
Clinical safety and efficacy
Efficacy is initially established in a cell culture model of
parasite activity, as close to the human infection as pos-
sible. As well as knowing the potency of a new molecule,
it is important to also determine its speed of action (the
in vitro parasite reduction rate), and the stages of the
parasite lifecycle where the compound is active, in order
to start to estimate how effective it will be in humans
[29]. A therapeutic window between the predicted ex-
posure required for a therapeutic effect in the patient,
and the no adverse event limit (NOAEL) seen in preclin-
ical safety studies must be established. Since there is
sometimes a discussion over whether a physiological
change observed is adverse or not, it is useful to also
provide the margin compared to the no-effect level
(NOEL). The size of this margin needs to be discussed
on a case-by-case basis depending on the characteristics
of the adverse effect. For example, a three-fold or even
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monitored and are not considered serious, such as a re-
versible change in blood chemistry, but even a 100-fold
window may not be acceptable in the case of unex-
plained mortality. This is an area where independent,
expert, external review is critical. Molecules must also
have a good oral bioavailability, since molecules with
bioavailability less than 20% tend to suffer from high
variability of exposure, large food effects, and a need for
higher doses; these factors have a direct impact on the
size of the pill and the cost. The compounds should also
have reasonable solubility in gastric fluid, not only be-
cause of the impact on bioavailability, but because poorly
soluble molecules given at high doses often produce
gastrointestinal side effects [30]; this is a problem seen
with several current anti-malarial medicines. Since there
may be circumstances in which mass drug administra-
tion is adopted, particularly in an elimination context,
the ideal safety criteria for new medicines is exceedingly
high - comparable to that of a vaccine.
Resistance
Emergence of resistance to treatment is a risk for any in-
fection. The first priority is to determine if the new mol-
ecule is active against as wide a selection as possible of
the five species of the parasite that infect humans, Plas-
modium falciparum, P. vivax, Plasmodium malariae, P.
ovale and Plasmodium knowlesi [31,32], though a prag-
matic solution is to focus on P. falciparum and, in fewer
cases, P. vivax due to accessibility to parasites and cul-
ture conditions. A second priority is to ensure that there
is no cross-resistance against relevant laboratory-
adapted strains showing resistance to medicines already
in clinical use. Third, it is important to determine the
activity of a compound against primary clinical isolates,
particularly those from geographical areas known for
anti-malarial drug resistance. The final question is to as-
sess the risk of resistance selection in vitro to determine
how often relevant mutations or amplifications occur,
how easily these are selected and what is their fitness
cost and transmissibility relative to the wild-type para-
sites [33]. Such parameters never replace clinical experi-
ence, but serve as a guide and risk assessment as to
whether new molecules have a high, medium or low
propensity to be compromised by resistance.
To minimize the risk of resistance, emerging mole-
cules will be formulated within a fixed-dose combination
product. The drugs in a combination should not be
cross-resistant with one another, so that resistant para-
sites to one drug are then killed by the other. No single
component of therapy should be exposed to significant
numbers of parasites on its own in patients in the field.
An ideal for an ‘irresistible’ combination could be to
combine two molecules having closely matched humanpharmacokinetic cover and potency. However, it may be
difficult to find and partner molecules with such
matched profiles, but at least the longer-lasting partner
should be exposed to as small a number of parasites as
possible, once the shorter-lasting drug has disappeared.
Ultimately, there is a risk that resistance will emerge to
all drugs used against the malaria parasite, but the goal
is to have a combination that will withstand resistance
pressure for as long as possible during the period of the
elimination and eradication agenda, which some have
estimated to be a timeframe of at least 50 years.
Producing an affordable medicine: managing the cost of
goods
The manufacturing cost of a new medicine is an import-
ant and often-overlooked factor. The goal for a fixed-
dose artemisinin combination therapy was an adult dose
costing around $1. This has been an important but chal-
lenging goal for the research and development commu-
nity. Current public sector ACT prices are still around
$1.50 for the adult treatment, and $0.40 per child. This
is an impressive achievement, but even this goal is still
some distance from what is affordable to many patients.
It would be ideal to have an anti-malarial combination
therapy as affordable as a chloroquine treatment was
when it was used as monotherapy, costing less than 10
US cents. The challenge of new combination medicines
is to keep the costs of each individual component low,
as well as minimizing production and packaging costs
and hence provide a medicine that is affordable. The
foremost factor determining cost is the clinically effect-
ive dose in patients: most of the APIs (Active Pharma-
ceutical Ingredients) in artemisinin combination therapy
cost between $100 and $1,000 /kg to produce (at the
tonne scale), but some of these are used at total doses as
high as 3 g in adults. If new medicines can be found with
much lower human effective doses, for example around
30 mg, then the cost of the ingredient would be reduced
by 100-fold (all else being equal). As a parenthesis, new
generations of molecules with increased in vivo potency
would also allow new medicines to be tested as slow-
release formulations that can be used to achieve longer-
term protection. Interestingly, even long half-life oral
drugs can benefit from slow release since a well-
absorbed drug can gain an additional 24 hours from for-
mulation. For transdermal patches or depot formula-
tions, the active molecules must be hydrophobic, and
even for such compounds there is a limit on capacity;
currently the maximum dose of any medicine delivered
by such technologies is around 10 mg per day [33]. This
is a far cry from the current ACT partners, where total
drug dosing can be as high as 3.5 g over three days.
The ease of synthesis and, ultimately, production is
critical: a small number of synthetic steps, each with
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also play a role in reducing costs. Lowering the clinical
dose generally also reduces variation in exposure and
produces fewer side effects, especially the gastrointes-
tinal irritancy caused by high-dose, poorly soluble medi-
cines as discussed above. Packaging and manufacturing
costs are often overlooked, and can represent a signifi-
cant proportion of the overall costs. Compact, simple
packaging helps reduce pricing. Figure 1 shows the rela-
tive cost structure for a representative anti-malarial
medicine [22]. Of note is the fact that absolute pack-
aging costs are similar for small infants as for adults,
therefore packaging becomes a larger proportion of the
overall cost for the pediatric formulations. These costs
would be drastically reduced by cheap single-dose cures,
which could be dispensed by healthcare workers. Mole-
cules must demonstrate stability under conditions of
high relative humidity and ambient field temperature
(37°C and 75% relative humidity), which is quite a differ-
ent standard to that required for a drug for a Western
market. With artemisinin combination therapy there
have been examples of endoperoxides reacting with the
partner or excipients in the tablet during storage, there-
fore, requiring bi-layer tablets with inert barriers, an
innovative yet more expensive solution.
Target candidate profiles
The TCPs presented below summarize the four-five types
of molecule that are sought to facilitate the elimination
and eradication of malaria. Each profile describes a set of
attributes for a single compound, for which there should
be increasing confidence as a result of the regulatory pre-
clinical studies, and which should be confirmed by the
end of the human proof-of-concept (typically phase IIa)
trial. Each TCP details a ‘Minimum Essential’ and an ‘Ideal’
profile. The ‘Ideal’ criterion builds on what is described in
the ‘Minimum Essential’; therefore, criteria are not re-
peated unless there is a change. The ‘Ideal’ profile, as
stated earlier, requires excellent safety as well as efficacy
since administration to asymptomatics, under eliminationFigure 1 Example of cost breakdown of artemether
lumefantrine ($1.50; R Bryant, personal communication for the
API costs).tactics, is conceivable. It is possible that one molecule may
fulfill all the requirements of two different TCPs. This is
the case for primaquine which has good clinical activity
against P. vivax relapse, and can also, with a different dos-
ing regimen, be used to prevent transmission of Plasmo-
dium. Figure 2 summarizes the current experience of how
these four-five profiles can be combined into a single
medicine. Two ideal medicines are described: the ideal
treatment or Single Exposure Radical Cure and Prophy-
laxis (SERCaP), and the ideal chemoprotection or a Single
Exposure Chemoprotection (SEC). It is important to
underline that these represent ideals, and that during de-
velopment of combinations then some trade-offs will have
to be made. Hence in each case there are definitions of the
current view on a minimally acceptable profile. Figure 3
describes how the different TCPs map onto the Plasmo-
dium life cycle.
TCP-1: ‘Fast clearance’, reducing the initial parasite burden
The cornerstone of malaria treatment is the availability
of at least one molecule capable of rapidly clearing the
parasite load. In order to be effective, a compound ad-
dressing TCP-1 (Table 1) would need to remain active
for long enough to make a significant impact (>6 log
unit reduction) on decreasing the initial parasitaemia.
The precise definition of how much activity results in a
clinically meaningful reduction in disease, as measured by
a decrease in adequate clinical and parasitological re-
sponse (ACPR) at 28 days after treatment, is still an open
question. This is an area where more clinical data on new
compounds will help to fill the gap and re-infection as a
function of immunity and transmission intensity will need
to be factored in. The gold standards for this profile are
the artemisinin derivatives, which dramatically lower para-
site numbers over three days of treatment by at least four
log units, leaving the remaining parasites to be killed by
the partner in the combination. An important point here
is that this speed of killing needs to be defined in humans:
in vitro and in vivo studies can be used to predict how
close any molecule in lead optimization is to the candidate
definition, but these are only projections. The MMV ex-
perience has been that for success, compounds should
typically have in vitro activities with an EC50 < 10 nM
against laboratory-adapted strains and clinical isolates,
and a single-digit mg/kg activity ED90 in the P. falciparum
infected human erythrocyte-engrafted SCID mouse model
[34]. The rate of clearance of parasites for this TCP is also
key; the expectation is that molecules will have a parasite
reduction rate (the fold reduction in parasitaemia over
one life cycle) at least as fast as 4-aminoquinolines, and
ideally faster than artemisinin derivatives. Preclinical
models of rates of killing and parasite clearance in vitro
and in vivo can be used to predict this in humans,
although these may be underestimated, since they do not
Figure 2 Breakdown of the ideal medicine into different target candidate profiles.
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reticulocytes or erythrocytes [29]. In the ideal case, where
the molecule is part of a SERCaP, the molecule would
need to produce at least a 106-fold parasite reduction
following a single oral encounter of one (or two) doses.
For the minimum criteria, a medicine which produces theFigure 3 Diagram of the Plasmodium lifecycle and parasite load (z-axsame effect over two to three days could still represent a
clinically relevant alternative to current regimens though
would need differentiating qualities to demonstrate advan-
tage and justify investment. This reduction in parasite
burden then needs to be confirmed clinically, measured by
the proportion of patients who are cured as reflected byis,logarithmic) with stages targeted by the various TCPs.
Table 1 TCP-1
TCP-1 criteria at human proof of concept Minimum essential Ideal
Dosing regimen; adult dose* Oral, one-three doses; <1,000 mg Oral, single dose; <100 mg
Rate of onset of action and clinical
parasite reduction ratio from single dose
Immediate and rapid clearance of parasites at least
as fast as chloroquine; > 6 log unit total
reduction in parasites
Immediate and rapid clearance of parasites at
least as fast as artesunate; > 6 log unit total
reduction in parasites
Susceptibility to loss of efficacy due
to acquired resistance
Low (better than atovaquone); no cross resistance
with TCP-2
Very low (similar to chloroquine); no cross
resistance with TCP-2. Resistance markers
identified
Clinical efficacy from single dose (day 7)
including patients from areas known to be
drug-resistant to current first line medications
100%
Clinical efficacy from single dose (ACPR at
day 28 or more, per protocol, PCR-corrected)
>50% >95%
Bioavailability /Food Effect - human data >30%, <3-fold >50%, none
Drug- drug interactions No unmanageable risks No interactions with other anti-malarial, anti-
retroviral or TB medicines
Safety - clinical Acceptable therapeutic ratio based on human
volunteer studies between exposure at human
effective dose and NOAEL, dependent on nature
of toxicity
Therapeutic ratio >50 fold based on human
volunteer studies between exposure at human
effective dose and NOAEL; benign safety signal
G6PD (Glucose-6-phosphate dehydrogenase)
deficiency status
Measured - No enhanced risk in preclinical data from
relevant G6PD deficient animal models
Measured - No enhanced risk in G6PD
deficient subjects
Formulation Acceptable clinical formulation identified
Cost of active ingredient in final medicine Similar to current medication: ≤$0.5 for adults,
$0.1 for infants under two years
Similar to older medications: <$0.25 for adults,
$0.05 for infants under two years
Projected stability of final product under
Zone IVb conditions (37°C 75% humidity)
≥ 6–24 months ≥1-5 years
*As discussed in the text, should frontline therapies be lost due to reduced efficacy or tolerability then a regimen over 3 days of dosing of novel well tolerated
candidates that overcome any resistance will be acceptable.
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response is required from a single agent to ensure an
ACPR of >95% as part of a combination. Lessons from
the artemisinins are instructive [35]. Four doses of
artemether monotherapy over 48 h leads to a cure rate
of just under 50% ACPR at day 28; when combined with
lumefantrine over the same dosing period the combined
cure rate is >98%. Further studies are currently planned
to investigate this clinically with the newer fast clear-
ance compounds, such as OZ439 and NITD609 [6-8],
and also to model the ACPR from parasite reduction
rates and pharmacokinetics, but this is a work in pro-
gress, and no hard and fast rules can be proposed at this
stage. The molecule needs ideally to show good activity
in vitro against the blood stages of all five Plasmodium
species which infect humans, although activity in P. fal-
ciparum and P. vivax are generally assumed to suffice,
particularly since parasites and assays for the others are
not readily available. TCP-1 can be summarized in the
ideal case as a molecule that should be similar in activ-
ity to an artemisinin derivative but with pharmacoki-
netic properties such that it would allow for less
frequent administration and even administration in a
single sitting preferably with matched elimination PK
and potency with a partner TCP-2 compound.Finally, it needs to be stressed that in countries or dis-
tricts where all of the current therapies are incapable of
producing an ACPR because of the emergence of resist-
ance, the balance of the objectives changes. The priority
in this case would be for molecules which are active
against all existing resistant strains, rather than simplifi-
cation of the treatment regimen.
TCP-2: long duration partner to complete the clearance of
the blood stage parasites
A candidate in this category is a long-acting compound,
capable of killing the residual parasites not eliminated by
the rapid-clearance TCP-1 medicine (Table 2). Ideally, a
compound fulfilling TCP-2 should be able to maintain its
plasma concentration above the minimal parasiticidal
concentration (MPC) for between two and four weeks
(typically needed in high transmission areas with high
reinfection rates), thus providing significant post-treatment
prophylaxis as measured by non-PCR corrected ACPR at
day 28. The MPC is defined as the concentration above
which the maximum rate of parasite killing is obtained.
This can be measured in vitro in a time-dependent viability
assay, or in vivo by examining the parasite-drug concentra-
tion response over time and at different doses. Given the
complexities of the biological systems, it is believed that
Table 2 TCP-2
TCP-2 criteria at phase IIa Minimum essential Ideal
Dosing regimen; adult dose* Oral, one-three doses; < 1500 mg Oral, single dose; < 100 mg
Rate of onset of action and
Clinical Parasite Reduction Ratio (PRR)
Dependent on TCP-1 partner. Together with
TCP-1 must deliver >95% cure
≥12 log unit reduction in asexual blood
stage load. Monotherapy cure
Susceptibility to loss of efficacy
due to acquired resistance
Low (better than atovaquone); no cross
resistance with TCP-1
Very low (similar to chloroquine); no cross
resistance with TCP-1. Resistance markers identified
Clinical efficacy from single dose
(ACPR at day 28, per protocol)
>80% PCR-corrected >95% non PCR-corrected
Bioavailability / food effect - human > 30%/ < 3-fold food effect > 50%/ no food effect
Drug-drug interactions No unmanageable risks No interactions with other anti-malarial,
anti-retroviral or TB medicines
Safety - Clinical Acceptable therapeutic ratio based on human
volunteer studies between exposure at human
effective dose and NOAEL, dependent
on nature of toxicity)
Therapeutic ratio >50 fold based on human
volunteer studies between exposure at human
effective dose and NOAEL; benign safety signal
G6PD (Glucose-6-phosphate
dehydrogenase) deficiency status
Measured - No enhanced risk in preclinical
data from relevant G6PD deficient
animal models
Measured - No enhanced risk in G6PD
deficient subjects
Formulation Acceptable clinical formulation identified
Cost of single treatment Similar to current medication: < $0.50 for
adults, $0.1 for infants under two years
Similar to older medications: < $0.25 for
adults, $0.05 for infants under two years
Projected stability of final product
under Zone IVb conditions (37°C 75% humidity)
≥ 24 months ≥ 5 years
*As discussed in the text, should frontline therapies be lost due to reduced efficacy or tolerability then a regimen over 3 days of dosing of novel well tolerated
candidates that overcome any resistance will be acceptable.
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value – which ultimately is measured in a Phase Ib Human
Challenge or Phase IIa Clinical study. The total parasite re-
duction of the current gold standards (4-aminoquinolines
and aminoalcohols) is impressive. Compounds such as
mefloquine can maintain a blood concentration above the
MPC for more than a month, which combined with a para-
site reduction rate of 1.5 log units per day, gives an ex-
tremely impressive (although theoretical) maximum
parasite reduction. The relationship between the duration
that MPC is maintained and the post-treatment prophy-
laxis period is however not clear: mefloquine maintains
these concentrations much longer than piperaquine, how-
ever piperaquine gives superior post-treatment prophylaxis
[36]. Identifying molecules with such a long half-life is a
challenge. This is because such drugs normally have high
metabolic stability and high affinity for tissue membranes
(such as phospholipids); consequently most drugs with
exceptional half-lives are lipophilic bases. Such drugs are,
therefore, likely to be promiscuous for many human recep-
tors and cause frequent adverse events. In addition they
may partake in reversible metabolic clearance steps such as
entero-hepatic recirculation, which will contribute to
variability and the challenges of development.
Most compounds used in screening come from diversity
collections which have been specifically targeted against
diseases in Western markets, for which the goal has often
been once daily therapy. Furthermore, molecules withextremely long human half-lives (several weeks) pose add-
itional challenges in development, in terms of the design
of toxicological and early clinical studies. A further prob-
lem is that the data on fast-killing molecules such as arte-
misinin, suggest that the logarithmic parasite reduction
rates are not additive: a combination of two medicines
does not necessarily increase the parasite clearance rate
over the fastest compound alone. A simple way of viewing
this is that the parasites can only be killed once. The sec-
ond compound is needed to kill remaining parasites, and
during the time that it is present as monotherapy there is
a risk of resistance generation whilst the ‘resistance win-
dow’ is open. That is when the compound is still above its
MPC for wild-type parasite, and hence providing a select-
ive pressure, yet the concentration is below the MPC for
any resistant parasite [37].
TCP-3: targeting Plasmodium in the non-dividing parasite
stages
As well as possessing erythrocytic-stage killing activity,
an ideal combination would need to contain compounds
which can prevent the relapse of dormant liver stages
(hypnozoites) and the sexual stages of the parasite in the
human host or in the mosquito vector. It is possible that
a single molecule could be identified with all of these
activities. The gold standard for this medicine is prima-
quine, which is the standard of care for preventing P.
vivax relapse due to its effects on hypnozoites, as well as
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quine has two characteristics which need to be improved
on. First, it needs to be given for 14 days to reliably kill P.
vivax hypnozoites for radical cure, and although it has
been suggested this could be reduced to seven days by
increasing the dose [39], there are significant challenges to
ensuring compliance with a long course of treatment with
a medicine which does not provide any symptomatic relief.
Second, it causes significant haemolysis in patients with
G6PD deficiency, and shows some gastrointestinal adverse
events. An additional concern, resistance to primaquine,
has not been clearly observed, although this always re-
mains a background possibility (recently reviewed in [40]).
There is some debate about whether the haemolysis is
caused by the same reactive intermediate responsible for
the effect against the hypnozoite [41,42]. Ideally, a candi-
date is sought which has parent-derived pharmacodynam-
ics for a single-dose cure and is active against all the non-
dividing exo-erythrocytic forms, but without causing the
haemolysis; this is described by TCP-3 (Table 3).
It is of course probable that no new single molecule
will be found that can kill both the hypnozoites and pre-
vent transmission, and that these two roles will have to
be performed by different molecules in a combination
medicine. The anti-hypnozoite attributes needed can be
described by a subset of criteria, TCP-3a. Pragmatically,
an in vitro activity of EC50 <100 nM against hypnozoitesTable 3 TCP-3
TCP-3: general considerations Minimum essential
Dosing regimen Oral, once a day for up to 3 days - for us
artemisinin-combination therapie
Efficacy: TCP3aa Prevents 90% of relapses over a six m
Human adult dose <1,000 m
Efficacy TCP3b Prevents transmission to mosquito >90%
oral dose. Human adult dose <1,
Safety Acceptable therapeutic ratio based on hu
studies between exposure at human effe
NOAEL, dependent on nature of
G6PD (Glucose-6-phosphate
dehydrogenase) deficiency status
Therapeutic dose identified with change
concentration at day 7 of < 2.5 g/l
with moderate G6PD activity (
Drug-drug interactions No unmanageable risks
Formulation Acceptable clinical formulation id
Cost of single treatmentb Similar to current medication: $0.50 for a
infants for relapse and $0.05 for adults, $
for transmission blocking
Projected stability of final product




a Better precision on the clinical efficacy of the gold standard, primaquine in relaps
tafenoquine, which will be available in the summer of 2013.
b Estimates of the price elasticity of an anti-relapse therapy are extremely challengi
and the current treatment costs with primaquine (currently USD $0.04 per 15 mg tain a validated assay would be desirable, although ultim-
ately this number could be much higher if the com-
pound has extremely high plasma exposure and is well
tolerated in humans. Currently the only system available
for testing new medicines uses Plasmodium cynomolgi
infected primary rhesus hepatocytes, although assays for
P. vivax infection of human cells are under development
([43]; Sangeeta Bhatia, personal communication). The
other challenge is the safety margin, in terms of plasma
exposure at the EC90 and at the no-adverse effect level
in pre-clinical species. Treatments should, therefore, be
able to prevent relapses in a preclinical animal model or
in man without toxicity. P. cynomolgi-infected rhesus
monkeys have been the model of choice, with a gold
standard 8-aminoquinoline as the reference drug
[44-46], while new murine models have also been pro-
posed [34,47]. Clinical studies in migrant populations
(reviewed in [48]) allow for a relatively simple proof of
concept in humans. This ‘out of transmission’ model
provides a definitive measure of relapse prevention and
it is critical to back-translate and confirm the
predictivity and relevance of earlier preclinical models.
The attributes needed for clinical transmission-blocking
activity are much more difficult to define, but are
discussed as a subset of criteria in TCP-3b.
Artemisinin derivatives are capable of rendering stage






Prevents 90% of relapses over a year.
Human adult dose < 100 mg
on day 7 post
000 mg
Prevents transmission to mosquito >90% between 12 h




Therapeutic ratio >50 fold based on human volunteer
studies between exposure at human effective dose and




Therapeutic dose shows no significant change
in hemoglobin concentration
No interactions with other anti-malarial,




Better than current medication: < $0.50 for adults, $0.12
for infants under two years for relapse and < $0.05 for
adults, $0.01 for infants for transmission blocking
≥ 5 years
e prevention should be available from the phase II comparison with
ng. The price range varies from the cost of treating relapses should they occur
blet, so $1.12 for 14 days treatment).
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half-lives, and so there is a need for a combination of
anti-gametocyte activity combined with long-acting
pharmacokinetics or dynamics. There is no generally
agreed gold standard of activity required in an anti-
gametocyte assay. The standard membrane feeding assay
(SMFA) or mouse-mouse transmission models are cur-
rently the only intermediate assays that measure formal
transmission to the mosquito vector and a mammalian
host respectively [49,50]. The additional complication is
that primaquine, the gold standard, requires metabolic
activation in the liver, and this must therefore be borne
in mind when selecting the correct assay. Predicting the
efficacy required to achieve clinically significant trans-
mission blockade is not possible with any accuracy at
this stage; as an initial guideline it is suggested that mol-
ecules should reduce the number of oocysts by >90%, as
measured in a clinical study where mosquitoes feed on
human blood at various time points post oral dosing.
However, this is complicated by the fact that the link
between the standard membrane feeding assay and field-
based transmission studies still requires further clarifica-
tion [51]. It is to be expected that better understanding
of this will emerge over the next two years as more mol-
ecules are characterized in standard membrane feeding
assays whose activity can be compared to efficacy in
human proof-of-concept studies. The WHO has recently
recommended a single dose of 0.25 mg/kg of primaquine
as the gold standard for transmission blocking [52]. This
single dose is not anticipated to cause significant haem-
olysis in G6PD-deficient subjects (unlike the 14 day
course required for relapse prevention). In the absence
of primaquine resistance, this sets a very high barrier for
a new molecule to achieve, simply based on transmission
blocking alone.
In Table 3, the attributes are described for all TCP-3
molecules, those specific for anti-relapse compounds
(TCP-3a) and those for clinically relevant transmission
blocking compounds (TCP-3b). The latter group could
contain molecules which kill the insect stages of the in-
fection such as oocysts and sporozoites following inges-
tion of a blood meal. The challenge for such molecules
is achieving an effective concentration in the human
host for as long as mature infective gametocytes are cir-
culating and so will only be feasible if co-administered
with a rapid-acting gametocytocidal agent. Interestingly,
transmission blocking can also result from insecticidal
activity and ivermectin is currently under evaluation to
complement existing tools towards eradication.
Although in an ideal world, where the goal is a
SERCaP, there may also be a place for a molecule with
both transmission-blocking and anti-relapse activity as
part of a three-day course of therapy, together with the
current generation of artemisinin combination therapies.Hence for the minimal acceptable profile, a dose given
over two or three days could have a role in malaria
control and eradication.
TCP-4: chemoprotection
Ultimately, it would be better to prevent a population
from becoming infected rather than treating the patients
once they become symptomatic. In many disease areas,
vaccines can provide such protection after a single injec-
tion providing protection for a large majority of subjects
for as much as a decade. No such vaccine has ever been
produced for a protozoan parasite, and the history of mal-
aria control has relied successfully on chemoprotection
from the earliest days of quinine therapy.
There is a growing consensus on how malaria can be
eliminated from affected countries. This strategy consists
of active management of cases and their asymptomatic
neighbours with first-line therapy in the early stages,
followed by more intense programmes to break trans-
mission. These would be followed by measures to con-
tain reintroduction: either case detection by focal
screening, or chemoprotection.
As malaria incidence falls, the population in such coun-
tries could be expected to move from being semi-immune
to being non-immune. Prior to such ‘end-game’ strategies,
specific protection of sensitive populations such as preg-
nant women, infants, or children in zones with seasonal
malaria has been shown to have significant impact [12,16].
The challenge, of course, for these preventive medicines,
is that their safety profile should be equivalent to vaccin-
ation, where serious adverse events in the order of
1:20,000 would be considered problematic, but such a
safety profile can only be confirmed several years post
launch, and with adequate pharmacovigilance.
Chemoprotection can be achieved by: killing the sporo-
zoite, killing the liver schizonts, or killing the parasites as
soon as they emerge into the blood stream from the liver.
Chemoprotection might be used to prevent an outbreak
from spreading from an introduced index case to
neighbouring households, or to protect sensitive popula-
tions. The current gold standards for chemoprotection are
atovaquone/ proguanil and mefloquine, but both are far
from ideal. The frequency with which an anti-malarial
needs to be administered to achieve a high level of protec-
tion is key when the medicine is used for this purpose. A
once per month dosing would provide a significant
improvement over the current daily or weekly administra-
tions. A medicine which only needs to be used once per
outbreak would have a more significant advantage. Cost
will be an important driver: atovaquone/proguanil is a
combination daily prophylactic, with an adult cost of $5
per day, although these prices may fall now that the patent
protection is expiring. Mefloquine, given one dose per
week as mono-protection, is cheaper, costing around
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treatment costs around $0.50 in raw materials. Cheaper
ways to make mefloquine have been developed [53], redu-
cing the active pharmaceutical ingredient (API) cost to
around $400/kg, but prices are ultimately linked to
volume of demand. Demand may increase if the medicine
is shown to have benefit for the prevention of malaria in
pregnancy [54]. There is an additional key challenge for
TCP-4 (Table 4): in any population the medicines used for
suppressive blood stage chemoprophylaxis should be
different from that used to treat clinical cases of malaria.
Fortunately, TCP-4 does not require the compounds to
have a rapid onset of action though since the subject is
asymptomatic, and so could include compounds which
show a delayed-death phenotype, which have previously
been down prioritized for drug development [55].
An alternative approach to the design of long-acting
medicines is the production of a slow-release formula-
tion. In the 1960s this was achieved with cycloguanil
pamoate [56,57], where a single depot administration
produced long-term protection, but also resulted in the
emergence of DHFR (dihydrofolate reductase)-resistant
mutant parasites. Such an intramuscular depot would be
unacceptable from today’s safety perspective, since it
would need surgical removal if there were an adverseTable 4 TCP-4
TCP-4 criteria Minimum essent
Dosing regimen; adult dosea Oral, once per week; < 1
Rate of onset of action Slow onset of action (>48 h) aga
stages or causal liver stag
Susceptibility to loss of efficacy due
to acquired resistance
Very low risk for blood
Clinical protection from infection >95% protection from primary Pla
Transmission reduction to the mosquito
vector: inhibition of oocysts via vector




> 30%, < 3-fold food
Drug-Drug Interactions No unmanageable
Safety – Clinical Acceptable therapeutic ratio b
volunteer studies between exp




Measured - No enhanced ris
G6PD deficient animal
Formulation Acceptable clinical formulat
Cost of single treatmentb ≥ $0.5 for adults, $0.1 for infants
Projected stability of final product
under Zone IVb conditions
(37°C 75% humidity)
≥ 2 years
a It may be acceptable for a chemoprotectant that is clearly differentiated in otherevent. Developing such technologies for combination
therapies would represent an additional challenge.
Combinations of candidates: a TPP for malaria treatment
The challenge of combining these candidates to design
an ideal medicine against malaria (Table 5) is formidable.
There are still many unknown factors, not the least of
which is that only a limited number of new classes of
molecules have reached clinical evaluation. It is clear
that a single molecule can have more than one attribute:
a molecule can for example meet the criteria of more
than one candidate profile (Figures 4 and 5), but it is
essential that combinations of molecules will be needed,
not least to combat resistance.
Safety is clearly a paramount concern for any new medi-
cine. The challenge with developing new medicines
against malaria is that the current medicines are relatively
safe, and serious adverse events rare (less than 1:10,000).
This means that any new medicine will be expected to
measure up to such a standard, and that in turn requires
extensive safety monitoring after launch of a new product.
Confirmation that such safety has been achieved will only
come with extensive pharmacovigilance, across a wide
range of patient ethnicities. In countries planning malaria
elimination there has been much discussion of strategiesial Ideal
,000 mg Oral, once per month; < 100 mg
inst asexual blood
e activity
stage Very low; orthogonal mechanism
to treatment use
smodium infection >95% protection from all Plasmodia infections
(including relapses)
> 90%
effect >50%, no food effect
risks No interactions with other anti-malarial,





Therapeutic ratio >50 fold based on human
volunteer studies between exposure at human
effective dose and NOAEL; benign safety signal
k in relevant
models
Measured - No enhanced risk in G6PD
deficient subjects
ion identified
under two years < $0.25 for adults, $0.05 for infants under two years
≥5 yr
ways versus existing gold standard prophylactics to be dosed more frequently.
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ment (Figure 1). It is important to underline that for mass
drug administration the safety profile has to be even more
stringent, given the different risk-benefit balance of
administering medicines to subjects who may not have the
disease. Here, as with vaccines, even 1 in 10,000 adverse
events will be problematic. Aiming for a SERCaP places
considerable challenges in addition. Giving all the active
ingredients as a single dose increases the maximum
exposure of each individual molecule, and may reduce the
overall clinical safety margin. The benefits of a single dose
therapy from a compliance and delivery perspective have
to be carefully weighed against the potential risks.
The question of duration of treatment cannot be con-
sidered in isolation from the emergence of artemisinin-
tolerant strains of the parasite. In countries or districts
where artemisinin combination therapies are clinically
effective, then clearly the SERCaP brings considerable
advantages in terms of directly observed therapy, andTable 5 TPP-1 for the treatment of uncomplicated malaria in
Parameter to be demonstrated for the combination
in clinical evaluation
Min
Rate of onset of action At least one
patient fe
Proportional Reduction in Parasite Load >12 log unit r
Clinical efficacy (day 7) including patients from areas
known to be drug-resistant to current first-line medications
Clinical efficacy (ACPR at day 28 or later, per protocol) >95
Transmission blocking No: preclinica
validated as pre
Relapse prevention: prevents the relapse of P vivax,
and by inference P ovale.
No: preclinica
validated as pre
Bioavailability/ Food Effect >30% for e
Drug-drug interactions No unmanage
state or phar
Dosing regimen Oral,
Safety Few drug r





Cost of treatment course ≤ $1.00 for
un
Shelf life of formulated product (ICH guidelines
for Zones III/IV; combination only)
Susceptibility to loss of efficacy due to acquired resistance Low (bette
pyrimeth
nopotential cost savings, since packaging and distribution
will be much simpler (Figure 3). In these countries or
districts a new three day course of treatment will offer
much less of an advantage. The cost of goods may be
lower, but this is set against the extensive clinical safety
database for ACT. The rationale for developing a new
therapy for this particular segment is much more chal-
lenging. However, in the countries and districts where
artemisinin combination therapies are no longer effect-
ive, because of artemisinin ineffectiveness rather than
resistance to the partner, then the scenario is different.
Here, a three-day course of treatment with similar safety
and efficacy as the current ACT would be acceptable. A
single dose cure would still be an advantage, but the
risk-benefit calculation would be different. The challenge
for drug development is three-fold. Without a molecular
biomarker for ‘artemisinin resistance’, it is difficult to
assess currently how many people fall into this high-risk
group. Second, in any case, there are no models showingchildren and adults
imum essential Ideal SERCaP
component acts rapidly;
ver decreased at 24 h
Both components act immediately; patient
fever decreased within 24 h
eduction in asexual blood
stage load
100% 100%
% PCR-corrected > 95% non PCR-corrected
l models still need to be
dictors of clinical outcome
Yes
l models still need to be
dictors of clinical outcome
Yes
Confirmation in clinical studies capable
of distinguishing prevention from delay
ach molecule, <3-fold >50% for each molecule, none
able risk in terms of solid
macokinetic interactions
No risks in terms of solid state
or pharmacokinetic interactions
two-three doses Oral, once
elated SAEs in phase III No drug related SAEs; minimal
drug-related AEs
bligatory due to low risk No enhanced risk
indicated in second and
hird trimester
Not contra-indicated
ed tablets or equivalent,
masking for pediatrics
Co-formulated tablets for adults. Dispersible
or equivalent with taste
masking for pediatrics
adults, $0.25 for infants
der two years
≥ 2 years ≥ 5 yr
r than atovaquone or
amine monotherapy);
cross resistance
Very low (similar to artemisinin
or chloroquine); no cross resistance.
Resistance markers identified.
Figure 4 Definition of the TPPs for elimination and eradication.
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with ACT will develop over the next decade. Third, cur-
rently there are not sufficient numbers of patients with
reduced parasite clearance rates to enable clinical studies
of new therapies, and in any case the public health prior-
ity is to eliminate the parasite in these regions.Figure 5 The positioning of new potential therapies, against a backg
'artemisinin resistance', and the advantages of a single dose cure.After considerations of safety and efficacy, the princi-
pal concern for a SERCaP will be to avoid the develop-
ment of resistance. If the SERCaP is to help in driving
malaria eradication it would be best if it did not have to
be regularly cupgraded’, as happens with many vaccines
against common bacterial or viral pathogens, and someround of the competing challenges of the development of
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that no one molecule is exposed to a large number of
parasites on its own. The way this is achieved with an
artemisinin combination therapy is that the artemisinin
analogue reduces the parasite numbers by at least 4 log
units over a three-day course, though this still leaves a
maximum of 108 parasites for the partner to face alone.
The closest current gold standard combination against
which to judge a SERCaP would therefore be an ACT
plus primaquine (to prevent transmission). This is a
combination of TCP-1, -2 and -3b. However, an ACT
plus primaquine fails to meet the TPP because single
dose primaquine does not prevent relapse. Other combi-
nations are of course possible. The problem of leaving a
partner to face the parasite alone is mitigated by having
TCP1s with higher rates of parasite clearance than the
artemisinins (clearly a major challenge) or extended du-
rations of exposure (to ensure a greater overall reduction
in parasite burden). The ultimate mitigation, however, is
a strategy of matched pharmacokinetics and potency (for
example a combination of two TCP-1 molecules plus a
TCP-3, all with similar pharmacokinetic-potency charac-
teristics). Clinical data suggests that logarithmic additiv-
ity in parasite killing activity should not be assumed
with anti-malarial combination treatments: for example,
the parasite reduction over time with artesunate-
mefloquine is no faster than artesunate [58]. These ob-
servations are also reflected in in vitro measurements of
the parasite reduction rate with combinations (L. Sanz,
unpublished data). Thus, for compounds with matched
pharmacokinetics where no logarithmic additivity is
seen, both molecules are likely to need to achieve a
PCR-corrected ACPR of greater than 95% as single
agents. This additional stringency may make it difficult
to identify suitable candidates. Should additivity be ob-
served, as a result of complementary stage specific ac-
tion then the individual ACPR will be less. In addition,
a combination of two short-acting molecules will pro-
vide poor post-treatment prophylaxis and hence not
deliver a formal SERCaP; operationally this could be a
major disadvantage in high-transmission areas. An-
other interesting question is whether the gametocyte-
killing activity needs to be in the TCP-3 molecule; a
TCP-1 molecule with additional anti-gametocyte prop-
erties would allow a TCP-1/3b, TCP-2, TCP-3a com-
bination, for example. Although several of the new
fast-killing TCP-1 candidates have highly potent activ-
ity against stage V gametocytes, it is not clear yet
whether this is sufficient to block transmission in a
clinically meaningful way. Artemether is an excellent
killer of gametocytes in culture, but artemether-
lumefantrine does not successfully block transmission
on its own, presumably due to the poor pharmacokin-
etics of the artemisinins [51,59].A TPP for a new medicine for chemoprotection
In any disease eradication agenda, preventing the popu-
lation from becoming infected is a key activity. In mal-
aria this has been primarily achieved to date with bed
nets. Vaccination is another strategy, but apicomplexan
parasites have developed sophisticated immuno-evasive
strategies. Chemoprotective medicines offer an add-
itional approach to disease control (Table 6). These
medicines could be used to protect vulnerable popula-
tions, and also in the situation where there was an out-
break of malaria in an area previously shown to be
malaria-free. This medicine would contain a combin-
ation of two anti-malarial APIs based on TCP-4 since its
widespread use would raise significant concerns about
resistance emerging if used alone. Since prophylaxis can
come from causal or suppressive activity it is ideal if the
combinations partners target the same parasite stage. It
is preferable for the medicine to be given infrequently.
Current chemoprotection regimens in children are given
monthly throughout the season. The technical challenge
of developing a medicine which can protect for several
weeks is enormous, and will require extensive safety
studies. Within the chemoprotection concept are also
the medicines for intermittent presumptive treatment
for pregnancy (IPTp) and its equivalent in infants
(termed IPTi) and children, (termed either IPTc) or sea-
sonal malaria chemoprotection. Over the next decade,
these therapies are most likely to involve new combina-
tions of existing registered medicines, but in the longer
term new classes of medicines will be needed. Cost is an
important driver here: as the incidence of malaria falls to
a level where elimination is feasible or achieved then the
cost-benefit ratio of chemoprotection increases.
Other TPPs: severe malaria
The standard of care for severe falciparum malaria
including cerebral malaria is now shifting from quinine
to parenteral artesunate, based on recent clinical results
obtained in South-East Asia and in sub-Saharan Africa
[60,61]. The prevalence of severe malaria will fall as the
total malaria numbers drop, but the proportion of cases
that are severe may increase as the population loses
some of its immunity, and severe malaria will remain a
challenge until the very end of the eradication agenda.
As the frequency of malaria cases falls, the risk of
late or even incorrect diagnosis increases (as is seen in
European travellers who return home), increasing the
risk of severe disease that is not or inappropriately
treated. A number of considerations apply to a new
treatment for severe malaria. First, in the absence of a
failure of artemisinin treatment due to acquired drug
resistance it is unlikely that a new therapy could demon-
strate clinical superiority over artesunate, since this
would require extremely large numbers of severely ill
Table 6 TPP-2 for a new medicine for chemoprotection
Parameter to be demonstrated for the
combination in clinical evaluation
Minimum essential Ideal SEC
Dosing regimen Oral, once per week Oral, once per month
Rate of onset of action For asexual blood stage action – slow onset
(48 h) - before rapid killing
Clinical efficacy Prevents primary infection of Plasmodium
>95%
Prevents Plasmodium infection including relapse
>95%
Transmission blocking No Yes
Bioavailability/ Food Effect >30% for each molecule, <3-fold >50% for each molecule, none
Drug-drug interactions No unmanageable risk in terms of solid
state or pharmacokinetic interactions
No risks in terms of solid state or pharmacokinetic
interactions
Safety Few drug related SAEs in phase III No drug related SAEs; minimal drug-related AEs
Use in patients with G6PD deficiency Testing not obligatory due to low risk No enhanced risk
Pregnancy Not contra-indicated in second and
third trimester
Not contra-indicated
Formulations Co-formulated tablets or equivalent,
with taste masking for pediatrics
Co-formulated tablets for adults. Dispersible or
equivalent with taste masking for pediatrics
Cost of treatment course ≤ $1.00 for adults, $0.25 for infants under
two years
Shelf life of formulated product
(ICH guidelines for Zones III/IV; combination only)
≥ 2 years ≥ 5 yr
Susceptibility to loss of efficacy due to
acquired resistance
Very low; no cross resistance with partner Very low; no cross resistance and orthogonal
mechanism from those used in treatment
Burrows et al. Malaria Journal 2013, 12:187 Page 15 of 20
http://www.malariajournal.com/content/12/1/187patients (probably more than 10,000). Second, severe
malaria patients are by definition fragile. Before a new
medicine is tested in this group of patients it must
already be known to be safe and efficacious against un-
complicated malaria, otherwise there may be undue risks
to the patient. If new medicines for treatment of severe
malaria become necessary because of the widespread
failure of artemisinins it is likely that either i.v. quinine
will be reinstigated or the subset of TCP-1 molecules,
already shown to be effective in uncomplicated malaria
and for which an intravenous formulation is feasible, will
be investigated. This is a special case: monotherapy
would be considered adequate, since all patients would
be treated afterwards with an oral combination therapy.
Not all TCP-1 molecules will fall into this class, since
some of them may not be sufficiently soluble for paren-
teral use. Third, while there is clearly a need for adjunct
therapy to minimize the sequelae of severe malaria,
these molecules will already have been shown to have
clinical efficacy and high tolerability in studies before
they are tested in children with severe malaria. The
search for such medicines will largely come from investi-
gators working in other therapeutic areas.
How many candidate molecules are needed to produce
the next generation of medicines?
The increased investment in research and development
of new medicines over the last decade has increasedboth the strength and the diversity of the global portfolio
of anti-malarial medicines. The portfolio contains many
new chemotypes currently being tested in regulatory
non-clinical studies for the first time, all of which have
been discovered in the last six years [17]. In the last year,
three new medicines from the global portfolio
progressed into formal preclinical development, and the
evidence is that this trend is sustainable provided invest-
ment is maintained. The results from high-throughput
screening against living parasites, and the willingness of
the community to allow their existing large chemical
collections to be screened in assays developed by others,
gives confidence that this trend in the discovery of new
molecules can continue, provided that the resources are
available. A key question is how many new molecules
are needed to properly meet future clinical needs as
discussed previously, given the attrition rates in clinical
development. Benchmark data for success rates in drug
discovery and development are often difficult to inter-
pret, since they are always based on past successes.
Across the pharmaceutical industry data are collected by
the Centre for Medicines Research (CMR), but these
cover a wide spectrum of infectious disease, and may
miss malaria-specific details. MMV has collected data
from the malaria drug discovery and development pro-
jects that it has been involved with over the last ten
years, which are fairly similar to those from the CMR,
but reflect a much smaller sample size and also the ‘Me
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These data are summarized in Table 7, which shows a
12% success rate for preclinical candidates becoming
part of a launched medicine for MMV and a 4.4% suc-
cess rate for CMR. The lower number for CMR reflects
the recent difficulty in developing new classes of antibi-
otics [62].
In most disease areas success rates are tending to fall
over the long term, reflecting difficulties in target valid-
ation at one end of the drug discovery process, and
increasing stringency from the regulatory authorities at
the other end; the yearly rate of new drug approvals (all
areas) has remained mostly flat over the past 60 years, in
spite of tremendous increases in expenditure on R&D
[63]. For neglected diseases, the use of whole parasite
screening avoids wasting efforts on non-valid targets,
and the close collaborative interactions with the regula-
tory authorities mean that there is a certain confidence
that our success rates, in established areas, will not fall
dramatically. If the success rate remains unchanged one
can predict the number of drug candidates that need to
be developed in order to produce a new drug. The over-
all probability P for ending up with at least one launched
product starting with n candidates with individual suc-
cess probability s is described by the equation (1- P) =
(1- s)n, or n = log(1 – P)/log(1 – s), as derived from the
Negative Binomial Distribution. Using MMV’s empirical
value for s (0.12, see Table 7), and aiming for a 90%
overall probability of success (P) this would give us a
requirement for 18 candidate molecules to result in one
launched product. There is some level of confidence for
these probabilities as they are based on the experience of
finding molecules which have fast-killing activity of
blood stages. However, for the transmission-blocking
and anti-relapse compounds it is difficult to be so
confident, since there is much less validation that the
associated in vitro assays can be used to predict clinicalTable 7 Success rates and costs for development of an anti-m
data from the Centres for Medicines Research (2008–11)








aA stage success rate of 75% for combining two medicines has been added in to re
development of a combination. The same correction has been used for CMR and M
sufficiently large to enable this to be accurately estimated.
bThe cost per phase is based on MMV project costs, and does not allow for in-kind
staff costs.
cThe estimate for phase III costs is taken from the pyronaridine-artesunate project, w
carried out. This does not include internal project management costs.reality, and in addition the parasites are generally non-
dividing at this stage and therefore have a narrower
range of potential molecular targets. The long-term de-
velopment of a triple-combination medicine containing
three new molecules would require as many as 30–40
new candidate molecules, in a world where as a global
drug discovery community we are discovering only two
or three new candidates per year. Even with the current
strong portfolio there is still a need for at least another
decade of drug discovery, and another one of develop-
ment beyond that.
Discussion
The call for an Agenda for Malaria Eradication has set
new challenges for all those engaged in the drug discov-
ery process. New medicines are needed to back up the
current gold standard ACT therapies, so as to provide
immediate alternative control strategies should the re-
duced speed of action of artemisinin spread. In addition,
new medicines are needed to prevent transmission and
relapse, the causes of new disease episodes. Finally, all
medicines have to be as safe and convenient and cost-ef-
fective as possible, which represents an additional
challenge. These increased demands are set against a
background of two additional difficulties. First, the over-
all resource of drug discovery in neglected diseases is
still relatively small, and in any case the overall product-
ivity of drug discovery (for all indications) is decreasing.
Second, the availability of human, Anopheles and Plas-
modium genomic information has not had an immediate
impact; progress in biological understanding paradoxic-
ally has led to overshooting rational drug discovery
efforts with excessive confidence in the power of reduc-
tionism. On the positive side, success rates for finding
new chemical series have increased with improvements
in high-throughput screening using live parasites and
the use of large, wide-diversity compound collections,alarial medicine (2007–12), compared with benchmark







flect the potential for unfavourable drug-drug interactions that prevent further
MV success rates, although our experience of these studies is currently not
contributions from our pharmaceutical partners, or for the internal MMV
here all the clinical costs were borne by MMV, and four pivotal studies were
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series to work on [17]. These hits are now in turn yield-
ing new targets, often previously understudied by the
community, which will help set an agenda for more
mechanism-based approaches with higher confidence in
target validation in the future.
The availability of new chemical series to work on has
underscored the need for clarity about the type of mole-
cules which are needed to achieve the malaria eradica-
tion agenda. These goals are essential to guide the
medicinal chemistry process needed to identify appropri-
ate candidates. Building on existing therapies and future
clinical needs, TCPs have been described for a rapid-
onset molecule, a long-acting molecule, one that pre-
vents relapse and stops transmission, and one that will
act as a chemoprotectant. An analysis of the current suc-
cess rates of drug development shows that for a 90%
chance of registering a molecule as many as 20 different
preclinical candidates may be required, of which some
already exist. The challenge is that much of the existing
portfolio is focused on the TCP-1, the rapid-clearance
molecule. This has led to a relative dearth of new mole-
cules with long half-lives, those which can kill the non-
dividing forms of the parasite, and those active against
sexual stages of the parasite. One of the priorities for
anti-malarial drug discovery is to ensure that there is a
standardized measurement of the activity of clinical can-
didates across the whole life cycle of the parasite, termed
the Malaria Life cycle Fingerprint [64].
The way in which candidate molecules are combined
to fulfill the final target product profiles shows that there
is a certain amount of flexibility depending on the actual
attributes of the molecules themselves. Theoretically,
several different ways of configuring a new combination
medicine can be envisioned. These include the combin-
ation of the first three target candidate profiles (TCP-1, -
2 and −3), preferably with matching half-lives and even
combinations which allow for one molecule having more
than one attribute (TCP-1/3b, TCP-2, TCP-3a). However,
in discussions of potential combinations the reality is
often more simple than the theory. Discussions about
potential partnering strategies for new molecules in
phase IIa, such as the endoperoxide OZ439 [6,7] or the
spiroindolone NITD609 [8], highlight that these mole-
cules can only be combined with molecules which have
already been shown to be active in phase IIa. This largely
limits the choice of TCP-2 candidates to the known
4-aminoquinolines or amino-alcohols, or to molecules of
antibacterial origin. Each of the 4-aminoquinolines or
amino-alcohols has strengths and weaknesses in terms
of half-life, cost, pre-existing resistance and dosing.
However the process of reviewing potential partners
underlines the need for other new classes of TCP-2 can-
didates for the future. These will not be easy to find,since the chemical diversity currently available for screen-
ing is focused more around medicines that can be given
once per day. However, the availability of over 20,000 new
hits which kill the parasite may allow the sub-selection or
hit optimization of molecules with a long half-life; these
types of prioritization will become increasingly important
over the next few years. The other alternative is to com-
bine two fast acting compounds, for example the two new
agents OZ439 and NITD609. This has the advantage of
using molecules which have never been exposed to mal-
aria as single agents, which has a certain appeal. The
plasma exposures of both molecules remain above the
minimum parasiticidal concentration for around a week,
and so it would not be expected that such a combination
would provide the same post-treatment prophylaxis as the
current ACT, although this is less of an issue in low-
transmission settings since reinfection rates are lower.
The choice of TCP-3 molecules (preventing relapse
and transmission) is even more stark. Currently the only
option is the 8-aminoquinoline primaquine, which
requires 14 days of therapy. An analogue, tafenoquine, is
in clinical trials to determine whether it can be effica-
cious and safer than primaquine as a single dose. New
families of active molecules are starting to be prioritized,
but so far none has reached clinical development. It is
important to underline that even with substantial invest-
ment in this area there are unlikely to be new molecules
with clinically proven activity within the next five years.
Putting all these molecules together to achieve a
single-exposure radical cure and prophylaxis is clearly
the ideal situation, but may be difficult to attain. To en-
sure adequate coverage from a single exposure, the dose
of each component will have to be high, and this inevit-
ably reduces the safety margin of the product. It is im-
portant to underline that whereas an ambitious objective
is laudable, then less dramatic improvements in the regi-
men (such as two doses in a day, or two days of dosing)
still represent a step in the right direction and should
not be discarded. In the regions where ACT is failing to
provide adequate treatment, then a three-day regimen
would be clinically advantageous.
The identification of TCP-4 as the cornerstone of the
chemoprotection agenda is also a critical issue. Once
again, there are few candidate molecules in the pipeline,
and this is an issue that has to be redressed. However,
there are also grounds for hope here. The fact that rapid
onset of action and fast killing are not required means that
there are already several scaffolds and target types which
could be studied for their relevance to TCP-4, including
previously discarded compounds with a delayed-death
mode of action. New medicines for chemoprotection must
be tested for their effects amongst people in malaria-
endemic areas, and designed for use by people in those
areas, rather than tourists or travellers.
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The Agenda for Malaria Eradication has set ambitious goals
for the treatment and chemoprevention of malaria, which
cannot be reached with the currently available medicines.
The combination of the complexity of drug discovery and
development, plus a timeline of over a decade from discov-
ery to launch in the first country, means that clarity at the
start of the process is critical for success. Acceptable and
ideal TPP for a treatment and chemoprotection agent have
been defined. These have then been broken down into con-
stituent parts - defined by the respective TCPs. As with any
retrosynthetic process, there are a number of different ways
the product can be broken down, and the final one chosen
will depend on the ease of identifying suitable molecules
for each TCP. The definition of target candidate profiles
has highlighted the extreme shortage of molecules for three
of the four profiles. Whilst there is some ground for opti-
mism that this gap will be closed over the next decade, it
will require a focused effort by the whole malaria drug dis-
covery community as well as a sustained source of funding.
In addition, well-validated, robust, functional assays for
hypnozoites and transmission blocking activity with proven
clinical correlations are required. Keeping a continued
focus of the community on such challenging end-goals,
through the TPPs, helps to ensure that the final products
are in line with the patient and public health needs of the
future. With such a focus, the community should be able to
partner to deliver new medicines with clinical improve-
ments over the current gold standards, and lead the way in
the eradication of malaria.
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